In 2002, Eli Lilly & Co. began to experiment with a radically new process for clinical development: rapid proof-of-concept (POC). It was by no means the first such experiment in the industry, but Lilly has been the only company to stick with it, institutionalizing the ideas in its quasi-independent Chorus division (See "Lilly’s Chorus Experiment," IN VIVO, May 2007 Also see "Lilly's Chorus Experiment" - In Vivo, 1 May, 2007.).
Now Chorus’ two top executives are going out on their own, setting up a Chorus-style competitor called Flexion Therapeutics Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?